Cigna (CI) Hikes Buyback Authorization, Boosts Shareholder Value

Cigna Corporation’s CI board of directors recently authorized an increase to its existing share repurchase program in a bid to return more value to shareholders. To this effect, the global health services company has inked accelerated stock repurchase agreements (the "ASR Agreements") with Morgan Stanley & Co. LLC and JPMorgan Chase Bank, N.A. as a result of which Cigna is entitled to buy back common shares worth $2 billion.

The latest authorization will result in the company receiving around 7.7 million shares in return of prepayment of $2 billion.

Cigna boasts of an impressive history when it comes to rewarding shareholders via share buybacks. Time and again, the company keeps on enhancing its buyback authority. Prior to the latest increase, Cigna’s buyback program was increased by $2 billion in July 2021. The company had hiked it by same amount in July and December of last year as well. Several other enhancements have also been made over the past few years.

In the first half of 2021, the company bought back 16.3 million shares worth roughly $3.7 billion. As of Aug 4, 2021, the company has around $3.8 billion remaining under its existing buyback program.

Continued share buybacks clearly hint toward the company’s sound capital position and its longstanding commitment to return substantial capital to shareholders. At a time when most companies temporarily suspended their share buyback programs, Cigna continued to pursue share buybacks amid the COVID-19 induced volatilities inflicted across 2020.

Besides share repurchases, Cigna remains committed to boosting shareholder value through dividend payments. This year, the company declared its first-quarter dividend for the first time. Previously the company used to declare dividends only once a year. However, it resorted to paying dividends each in the second and third quarter of this year. This year, the company raised its dividend significantly from 4 cents per share to $1.00. Its dividend yield of 1.9% compares favorably with the industry’s figure of 1.2%.

These initiatives highlight the operational and financial strength of the company. Cigna’s management remains optimistic about rewarding shareholders to the tune of over $7 billion in 2021 on the back of robust share buybacks and a significant uptick in dividend.

A robust financial position driven by a strong balance sheet and adequate cash generation capabilities over the years has paved the way for Cigna to undertake growth initiatives, and pursue accelerated and prudent capital deployment measures.

Zacks Rank & Price Performance

Shares of Cigna has gained 21.7% in a year compared with the industry’s rally of 31.4%.

Zacks Investment Research
Image Source: Zacks Investment Research

The stock has a Zacks Rank #4 (Sell).

Stocks to Consider

Some better-ranked stocks in the medical space include The Joint Corp. JYNT, Acadia Healthcare Company, Inc. ACHC and Universal Health Services, Inc. UHS, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Joint Corp., Acadia Healthcare and Universal Health Services have a trailing four-quarter earnings surprise of 235.00%, 26.14% and 29.01%, on average, respectively.

Time to Invest in Legal Marijuana

If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.

After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.

You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.

Today, Download Marijuana Moneymakers FREE >>

Click to get this free report

Universal Health Services, Inc. (UHS): Free Stock Analysis Report

Cigna Corporation (CI): Free Stock Analysis Report

Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report

The Joint Corp. (JYNT): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More